DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Pexeva (Paroxetine Mesylate) - Published Studies

 
 



Pexeva Related Published Studies

Well-designed clinical trials related to Pexeva (Paroxetine)

What if the Women's Health Initiative had used transdermal estradiol and oral progesterone instead? [2014]

One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. [2013]

Paroxetine in the treatment of dysthymic disorder without co-morbidities: A double-blind, placebo-controlled, flexible-dose study. [2013]

The paroxetine 352 bipolar trial: A study in medical ghostwriting. [2012]

Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a complete set of randomized placebo-controlled trials. [2011.11]

Combined Prolonged Exposure Therapy and Paroxetine for PTSD Related to the World Trade Center Attack: A Randomized Controlled Trial. [2011.09.09]

Neural correlates of antidepressant-related sexual dysfunction: a placebo-controlled FMRI study on healthy males under subchronic paroxetine and bupropion. [2011.08]

A randomized, controlled study comparing the effects of vestipitant or vestipitant and paroxetine combination in subjects with tinnitus. [2011.07]

Acupuncture versus paroxetine for the treatment of premature ejaculation: a randomized, placebo-controlled clinical trial. [2011.05]

Meta-regression analysis of paroxetine clinical trial data: does reporting scale matter? [2011.04]

Increased neural response to trauma scripts in posttraumatic stress disorder following paroxetine treatment: A pilot study. [2011.03.24]

Functional magnetic resonance imaging study on the effects of acute single administration of paroxetine on motivation-related brain activity. [2011.03]

Influence of metoprolol dosage release formulation on the pharmacokinetic drug interaction with paroxetine. [2011.03]

Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design. [2011.02]

A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression. [2011]

A randomized, controlled study comparing the effects of vestipitant or vestipitant and paroxetine combination in subjects with tinnitus. [2011]

Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a complete set of randomized placebo-controlled trials. [2011]

A review and Bayesian meta-analysis of clinical efficacy and adverse effects of 4 atypical neuroleptic drugs compared with haloperidol and placebo. [2011]

Specificity profile of paroxetine in major depressive disorder: meta-regression of double-blind, randomized clinical trials. [2011]

Slow vs standard up-titration of paroxetine in the treatment of panic disorder: a prospective randomized trial. [2010.12]

The impact of paroxetine coadministration on stereospecific carvedilol pharmacokinetics. [2010.12]

Comparison of paroxetine and amitriptyline as adjunct to lithium maintenance therapy in bipolar depression: a reanalysis of a randomized, double-blind study. [2010.11]

A randomized, controlled trial of aerobic exercise in combination with paroxetine in the treatment of panic disorder. [2010.10]

[Efficacy of escitalopram vs paroxetine on severe depression with associated anxiety: data from the "Boulenger" study]. [2010.10]

Heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine. [2010.09]

Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine. [2010.09]

Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a chinese population. [2010.08]

Two separate dose-dependent effects of paroxetine: mydriasis and inhibition of tramadol's O-demethylation via CYP2D6. [2010.07]

A randomized controlled study of paroxetine and cognitive-behavioural therapy for late-life panic disorder. [2010.07]

Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: escitalopram vs paroxetine. [2010.03]

Balneotherapy versus paroxetine in the treatment of generalized anxiety disorder. [2010.02]

A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). [2010.02]

Effects of paroxetine on emotional functioning and treatment awareness: a 4-week randomized placebo-controlled study in healthy clinicians. [2010.01]

Clinical features of patients with treatment-emergent suicidal behavior following initiation of paroxetine therapy. [2010.01]

Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale. [2010.01]

Heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine. [2010]

Clinical features of patients with treatment-emergent suicidal behavior following initiation of paroxetine therapy. [2010]

Effects of antidepressants on plasma metabolites of nitric oxide in major depressive disorder: comparison between milnacipran and paroxetine. [2009.11.13]

Cognitive behavioral therapy versus paroxetine in the treatment of hypochondriasis: an 18-month naturalistic follow-up. [2009.09]

Redistribution of slow wave activity of sleep during pharmacological treatment of depression with paroxetine but not with nefazodone. [2009.09]

History of depressive and/or anxiety disorders as a predictor of treatment response: a post hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release in patients with fibromyalgia. [2009.08.31]

Investigating the efficacy of paroxetine in developmental stuttering. [2009.07]

The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets. [2009.07]

Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. [2009.07]

A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study. [2009.05.26]

History of early abuse as a predictor of treatment response in patients with fibromyalgia: A post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release. [2009.04.20]

Superiority of escitalopram to paroxetine in the treatment of depression. [2009.04]

Effects of acute alcohol intoxication and paroxetine on aggression in men. [2009.04]

Treatment of social anxiety with paroxetine: mediation of changes in anxiety and depression symptoms. [2009.03]

Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy. [2009.03]

Childhood abuse and treatment response in patients with irritable bowel syndrome: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release. [2009.02]

The Effects of Desvenlafaxine and Paroxetine on the Pharmacokinetics of the Cytochrome P450 2D6 Substrate Desipramine in Healthy Adults. [2009.02]

A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome. [2009.01]

Low doses of controlled-release paroxetine in the treatment of late-life depression: a randomized, placebo-controlled trial. [2009.01]

History of early abuse as a predictor of treatment response in patients with fibromyalgia: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release. [2009]

Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine. [2008.12]

Low doses of controlled-release paroxetine in the treatment of late-life depression: A randomized, placebo-controlled trial. [2008.10.07]

Evidence Why Paroxetine Dose Escalation is Not Effective in Major Depressive Disorder: A Randomized Controlled Trial With Assessment of Serotonin Transporter Occupancy. [2008.10.01]

The effects of acute treatment with paroxetine, amitriptyline, and placebo on driving performance and cognitive function in healthy Japanese subjects: a double-blind crossover trial. [2008.07]

Luteal phase administration of paroxetine for the treatment of premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled trial in Canadian women. [2008.06]

Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. [2008.05]

Pharmacologic treatment of postpartum women with new-onset major depressive disorder: a randomized controlled trial with paroxetine. [2008.04]

Paroxetine CR augmentation for posttraumatic stress disorder refractory to prolonged exposure therapy. [2008.03]

Six-month paroxetine treatment of premenstrual dysphoric disorder: continuous versus intermittent treatment protocols. [2008.02]

Once-daily high-dose pindolol for paroxetine-refractory premature ejaculation: a double-blind, placebo-controlled and randomized study. [2008.02]

Paroxetine with pindolol augmentation: A double-blind, randomized, placebo-controlled study in depressed in-patients. [2008.02]

Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials. [2008.01.29]

Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis. [2008.01]

Paroxetine-induced modulation of cortical activity supporting language representations of action. [2008.01]

Paroxetine reduces social anxiety in individuals with a co-occurring alcohol use disorder. [2008]

History of depressive and anxiety disorders and paroxetine response in patients with irritable bowel syndrome: post hoc analysis from a placebo-controlled study. [2008]

Nocturnal urinary cortisol excretion over a randomized controlled trial with paroxetine vs. placebo combined with relaxation training or aerobic exercise in panic disorder. [2008]

Effects of milnacipran and paroxetine on overactive bladder due to neurologic diseases: a urodynamic assessment. [2008]

Paroxetine versus placebo and other agents for depressive disorders: a systematic review and meta-analysis. [2007.12]

Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics. [2007.12]

A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. [2007.11]

Paroxetine oral solution is bioequivalent to paroxetine tablets--advantages of the solution. [2007.11]

A randomized, single-blind, comparison of venlafaxine with paroxetine in elderly patients suffering from resistant depression. [2007.11]

A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. [2007.10]

Pharmacological Interaction Between 3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) and Paroxetine: Pharmacological effects and pharmacokinetics. [2007.09.21]

Maintenance treatment for old-age depression preserves health-related quality of life: a randomized, controlled trial of paroxetine and interpersonal psychotherapy. [2007.09]

Clinical observation on treatment of depression by electro-acupuncture combined with Paroxetine. [2007.09]

Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients. [2007.06.30]

[Effects of paroxetine with or without zolpidem on depression with insomnia: a multi-center randomized comparative study] [2007.06.19]

Quality of life and metabolic status in mildly depressed patients with type 2 diabetes treated with paroxetine: a double-blind randomised placebo controlled 6-month trial. [2007.06.15]

Once-daily duloxetine 60 mg in the treatment of major depressive disorder: Multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil. [2007.06]

Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. [2007.05.15]

Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial. [2007.05]

A randomized, controlled, trial of controlled release paroxetine in fibromyalgia. [2007.05]

A double-blind placebo-controlled pilot study of controlled-release paroxetine on depression and quality of life in chronic heart failure. [2007.05]

The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression. [2007.04.05]

Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. [2007.04]

Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters. [2007.02]

Cognitive behavior therapy and paroxetine in the treatment of hypochondriasis: a randomized controlled trial. [2007.01]

Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder. [2007.01]

Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects. [2007.01]

Determination of paroxetine in plasma by liquid chromatography coupled to tandem mass spectrometry for pharmacokinetic and bioequivalence studies. [2007]

A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. [2007]

A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. [2007]

Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram). [2007]

Improved insulin sensitivity in 80 nondiabetic patients with MDD after clinical remission in a double-blind, randomized trial of amitriptyline and paroxetine. [2006.12]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017